Table 2.
Analysis of presenting blood investigations done within anaemia pathways in preassessment clinic within PDSA cycle 1 (2017) and cycle 3 (2018)
| 2017 (n=62) | 2018 (n=61) | |
| Hb measured at PAC (g/L) | 135 (122–146) (88–159) | 132 (117–144) (77–179) |
| MCV (fL) | 90 (88–94) (70–105) | 88 (85–93) (66–109) |
| Ferritin concentration (μg/L) | 91 (31–177) (14–514) | 55 (29–161) (4–743) |
| Patients with Hb<130 g/L and ferritin<30 μg/L (iron deficiency anaemia) | 9 (14.5%) | 15 (24.6%) |
| Number of patients with Hb>130 g/L and ferritin<30 μg/L (iron deficiency) | 4 (6.4%) | 6 (9.8%) |
| Interventions | ||
| Intravenous iron* | 14/62 | 20/61 |
| Oral iron | Unknown | 2/61 |
| B12/folate | Unknown | 1/61 |
| No intervention | 48/62 | 32/61 |
| Unknown | 6/61 | |
| Intravenous iron dose (mg)* | 1000 (500–1000) | 1400 (1000–2000) |
| Time between intravenous iron and surgery (days) | Unknown | 116 (31–136) (20–194) |
| Adverse events related to intravenous iron infusion | 0 | 0 |
Values are median (IQR) (range) or number (proportion).
*In 2017, this was 1 g ferric carboxymaltose; in 2018, this was 20 mg/kg iron isomaltoside.
Hb, haemoglobin; MCV, Mean corpuscular volume; PAC, preoperative assessment clinic; PDSA, plan–do–study–act.